tiprankstipranks
Advertisement
Advertisement

PCVX Stock Latest News

Vaxcyte Announces Board Transition and New Director Appointment
Company AnnouncementsVaxcyte Announces Board Transition and New Director Appointment
21d ago
8K
PCVX
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
PremiumCompany Announcements
Vaxcyte Shareholders Reelect Directors, Approve Governance Measures
28d ago
8K
PCVX
Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines
PremiumCompany Announcements
Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines
28d ago
PCVX
Vaxcyte doses first participant in VAX-A1 study
PremiumThe Fly
Vaxcyte doses first participant in VAX-A1 study
1M ago
PCVX
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
PremiumThe Fly
Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77)
2M ago
PCVX
Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
PremiumThe FlyVaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial
4M ago
PCVX
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
Premium
The Fly
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
4M ago
PCVX
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
Premium
Company Announcements
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate
4M ago
PCVX
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
PremiumCompany Announcements
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans
5M ago
PCVX
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
PremiumRatings
Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028
5M ago
PCVX
Vaxcyte price target raised to $89 from $85 at BTIG
PremiumThe Fly
Vaxcyte price target raised to $89 from $85 at BTIG
5M ago
PCVX
Vaxcyte price target lowered to $133 from $134 at BofA
PremiumThe Fly
Vaxcyte price target lowered to $133 from $134 at BofA
5M ago
PCVX
Vaxcyte price target raised to $67 from $38 at Goldman Sachs
PremiumThe FlyVaxcyte price target raised to $67 from $38 at Goldman Sachs
5M ago
PCVX
Vaxcyte price target raised to $75 from $50 at TD Cowen
Premium
The Fly
Vaxcyte price target raised to $75 from $50 at TD Cowen
5M ago
PCVX
Vaxcyte Launches New $500 Million ATM Equity Program
Premium
Company Announcements
Vaxcyte Launches New $500 Million ATM Equity Program
5M ago
8K
PCVX
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
PremiumThe Fly
Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year
5M ago
PCVX
Is PCVX a Buy, Before Earnings?
PremiumPre-Earnings
Is PCVX a Buy, Before Earnings?
5M ago
PCVX
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
PremiumCompany Announcements
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors
5M ago
PCVX
Vaxcyte doses first participants in OPUS-3 trial
PremiumThe Fly
Vaxcyte doses first participants in OPUS-3 trial
5M ago
PCVX
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position
PremiumCompany AnnouncementsVaxcyte Completes Public Equity Offering, Bolstering Capital Position
5M ago
8K
PCVX
Vaxcyte 11M share Spot Secondary priced at $50.00
Premium
The Fly
Vaxcyte 11M share Spot Secondary priced at $50.00
6M ago
PCVX
Vaxcyte secondary being re-offered at $50 per share
Premium
The Fly
Vaxcyte secondary being re-offered at $50 per share
6M ago
PCVX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >